1356 ET - FMC has received interest from several parties as it explores strategic alternatives, including a merger or possible sale of the agricultural sciences company. "I'd say there is five to 10 parties which are interested in the process at different level in different manners," CEO Pierre Brondeau says at the JPMorgan Industrials Conference. Some of the interest has come from private equity, Brondeau says, and most of the interest is focused around the opportunities of FMC's pipeline of new products rather than concerns about the expiration of the patent for its Rynaxypyr product. The strategic options constitute a plan B for the company, Brondeau says, with plan A being to remain independent and continue restructuring and paying down debt.(elias.schisgall@wsj.com)
(END) Dow Jones Newswires
March 18, 2026 13:56 ET (17:56 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.